Skip to main content

Skye Bioscience, Inc. (SKYE)

OTCMKTS: SKYE · IEX Real-Time Price · USD
0.0690 -0.0010 (-1.43%)
Oct 19, 2021 3:57 PM EDT - Market closed
Market Cap29.37M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out476.11M
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume994,812
Open0.0680
Previous Close0.0700
Day's Range0.0670 - 0.0738
52-Week Range0.0650 - 0.2490
Beta0.49
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About SKYE

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based therapeutics for the treatment of infectious diseases. The company's lead product candidate is THCVHS, which is in preclinical trials for the treatment of glaucoma. It is also developing CBDVHS that is in preclinical trials to treat various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy; and Cannabinoid Cocktail for the treatment of anti-infective diseases. The company was formerly known...

IndustryBiotechnology
Founded2012
CEOBrian Murphy
Employees6
Stock ExchangeOTCMKTS
Ticker SymbolSKYE
Full Company Profile

Financial Performance

Financial Statements

News

Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

Exclusive sponsored research agreement with endocannabinoid research pioneers Exclusive sponsored research agreement with endocannabinoid research pioneers

1 week ago - GlobeNewsWire

Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with si...

2 weeks ago - GlobeNewsWire

Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering

SAN DIEGO, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecul...

3 weeks ago - GlobeNewsWire

Skye Bioscience Announces $7.0 Million Registered Direct Offering

SAN DIEGO, CA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecul...

3 weeks ago - GlobeNewsWire

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutic...

SAN DIEGO, CA, Sept. 21, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with s...

1 month ago - GlobeNewsWire

Skye Bioscience to Present at the H.C. Wainwright Ophthalmology Conference

SAN DIEGO, CA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseas...

2 months ago - GlobeNewsWire

Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies

THCVHS shows no signs of chromosomal or gene mutations in preclinical studies

2 months ago - GlobeNewsWire

Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors

SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecul...

2 months ago - GlobeNewsWire

Cannabis Industry Investor Presentations Now Available for On-Demand Viewing

NEW YORK, July 1, 2021 /PRNewswire/ -- Virtual Investor Conferences® and KCSA Strategic Communications today announced that the presentations from the June 29 th & 30th Cannabis Industry Virtual lnvesto...

Other symbols:ALEAFCLVRIMCCMRMD
3 months ago - PRNewsWire

Cannabis Industry Investor Conference: Company Executives Present June 29th & 30th

NEW YORK, June 22, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications and ATB Capital Markets today announced the agenda for the upcoming Cannabis Indust...

Other symbols:ALEAFCLVRIMCCMRMD
4 months ago - PRNewsWire

Skye Bioscience Completes CMC and GLP Production for THCVHS Lead Program

San Diego, Calif, April 22, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived mole...

6 months ago - GlobeNewsWire

Skye Bioscience to Present at Upcoming Investment Conferences in April

San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived mole...

6 months ago - GlobeNewsWire

Skye Bioscience Targets Unmet Needs Of Glaucoma Through Cannabinoids

Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this article in no way represents investment advice or opinion on the...

6 months ago - Benzinga

Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific...

San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-...

7 months ago - GlobeNewsWire

Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference

San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-...

7 months ago - GlobeNewsWire

Skye Bioscience Is Pursuing A New Kind Of Glaucoma Drug

The following article is sponsored by Skye Bioscience, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is inte...

7 months ago - Benzinga

Skye Bioscience to Participate in Investment Conferences in February

San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-d...

8 months ago - GlobeNewsWire

Skye Bioscience Is Utilizing A Novel THC-Derivative To Treat Glaucoma

Skye Bioscience, formally Emerald Bioscience, was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no ...

9 months ago - Benzinga

Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience

Name change reflects Company's evolution, renewed team and strategic focus on advancing its lead compound into human trials Company to trade under ticker SKYE effective January 19, 2021 Name change refl...

9 months ago - GlobeNewsWire

Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th

San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid...

9 months ago - GlobeNewsWire

Emerald Bioscience to Present at the KCSA Cannabis Investor Conference

San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary can...

9 months ago - GlobeNewsWire

Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of ...

Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma

10 months ago - GlobeNewsWire

Emerald Bioscience Creates Unique Path to Prevent Blindness Using Patented Synthetic Cannabinoids

The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids. The results could prove highly valuable to patients, as well as th...

10 months ago - Benzinga

Emerald Bioscience Provides Corporate Update

Renewed team and capital focused on advancing lead compound for glaucoma into human studies

1 year ago - GlobeNewsWire